1,454 reports of this reaction
1.6% of all SUNITINIB MALATE reports
#15 most reported adverse reaction
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is the #15 most commonly reported adverse reaction for SUNITINIB MALATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 1,454 FDA adverse event reports linking SUNITINIB MALATE to PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME. This represents approximately 1.6% of all 93,209 adverse event reports for this drug.
SUNITINIB MALATE has an overall safety score of 85 out of 100. Patients taking SUNITINIB MALATE who experience palmar plantar erythrodysaesthesia syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is a less commonly reported adverse event for SUNITINIB MALATE, but still significant enough to appear in the safety profile.
In addition to palmar plantar erythrodysaesthesia syndrome, the following adverse reactions have been reported for SUNITINIB MALATE:
The following drugs have also been linked to palmar plantar erythrodysaesthesia syndrome in FDA adverse event reports:
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME has been reported as an adverse event in 1,454 FDA reports for SUNITINIB MALATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME accounts for approximately 1.6% of all adverse event reports for SUNITINIB MALATE, making it a notable side effect.
If you experience palmar plantar erythrodysaesthesia syndrome while taking SUNITINIB MALATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.